drugset / Trial / NCT06848894

Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment

NCT06848894

Recruiting 1204 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to explore the efficacy and safety of Human Urinary Kallidinogenase for acute ischemic stroke patients receiving intravenous thrombolysis and/or endovascular treatment.

Timeline

Start
2025-03
Primary completion
2026-12
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Human Urinary Kallidinogenase Protein / enzyme biologic 0.15 unknown
Background sodium chloride Unknown 100 ml

Indications